Recent research in adult-onset SLE showed that a urinary panel including LPGDS, transferrin, AGP-1, ceruloplasmin, MCP-1 and sVCAM-1 predicted response to rituximab treatment at 12 months (AUC 0.818) [113]. This evidence concerns the gene CCL2 and systemic lupus erythematosus.